Continuation of The Collaborative Islet Transplantation Registry (CITR)

项目摘要 本申请作为对RFA-DK-21-013的响应，描述了一个全面的数据和统计协调 2022-2027年合作胰岛移植登记中心（CITR）。2017-2021年持续 作为CITR-DSCC，埃姆斯继续与NIDDK计划办公室、监督委员会 和CITR调查员，以支持已建立的CITR登记处。登记处包括同种异体和 自体胰岛移植，以及任何其他β细胞替代疗法，应该是 随访了以重度低血糖为标志的难治性血糖不稳定的疗效和安全性 1型糖尿病患者或因任何原因（包括治疗性）缺乏胰岛的患者 胰腺切除术或任何胰岛细胞功能丧失。更多详情，请参阅具体目标部分。

PROJECT SUMMARY This application, in response to RFA-DK-21-013, describes a comprehensive Data and Statistical Coordinating Center (DSCC) for the Collaborative Islet Transplant Registry (CITR) for 2022-2027. Continuing from 2017-2021 as the CITR-DSCC, Emmes continues to collaborate with the NIDDK Program Office, the Oversight Committee, and the CITR investigators to support the established CITR Registry. The registry includes allogeneic and autologous pancreatic islet transplantation, as well as any other beta cell replacement therapies that should be followed for efficacy and safety in the resolution of refractory glycemic lability marked by severe hypoglycemic episodes in persons with Type 1 diabetes or lacking pancreatic islets for any reason including therapeutic pancreatectomy or any loss of islet cell function. For more details, please see the Specific Aims section.